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http://dx.doi.org/10.1016/j.ccr.2012.12.007SUMMARYThe natural product englerin A (EA) binds to and activates protein kinase C-q (PKCq). EA-dependent activa-
tion of PKCq induces an insulin-resistant phenotype, limiting the access of tumor cells to glucose. At the
same time, EA causes PKCq-mediated phosphorylation and activation of the transcription factor heat shock
factor 1, an inducer of glucose dependence. By promoting glucose addiction, while simultaneously starving
cells of glucose, EA proves to be synthetically lethal to highly glycolytic tumors.INTRODUCTION
Many solid tumors are characterized by an altered metabolic
program and display increased dependence on glucose. Several
signaling pathways and transcription factors are critical for
providing sustained intake of glucose by tumor cells and for
enforcing their glycolytic dependence, including the insulin
signaling pathway (Leto and Saltiel, 2012) and the heat shock
transcription factor heat shock factor 1 (HSF1) (Dai et al.,
2007). Whereas a lack of function of the insulin pathway or
HSF1 has been linked to diabetes and aging, hyperinsulinemia
and HSF1 activation have been linked to the development of
cancer (Whitesell and Lindquist, 2009; Gallagher and LeRoith,
2011; Mendillo et al., 2012). Indeed, recent reports suggest
that dependence on HSF1 reflects the ‘‘nononcogene addiction’’
of tumor cells for this transcription factor (Solimini et al., 2007).
Molecular mechanisms underlying HSF1-enforced glucose
dependence are not well understood. However, effects of the
insulin pathway on glucose uptake and utilization have been
well characterized. Insulin and insulin-like growth factors acti-
vate the PI3K/AKT pathway to stimulate glucose uptake.Significance
Many epithelial tumors display a glycolytic phenotype charact
abnormal metabolism of such tumors has been a long-term go
tively activates PKCq to induce a metabolic catastrophe in glyc
iting glucose uptake, while simultaneously activating the heat
dependence. These data identify EA as a mechanistically uniq
228 Cancer Cell 23, 228–237, February 11, 2013 ª2013 Elsevier Inc.Numerous epithelial tumors rely on constitutive activation of
this pathway to increase their supply of glucose (Vander Heiden
et al., 2009; Leto and Saltiel, 2012). The protein kinase C (PKC)
family of kinases exerts both positive and negative effects on
this pathway (Nelson et al., 2008). In type II diabetes, activation
of some PKCs, including PKCq, with fatty acids or diacylglycerol
can induce insulin resistance via inhibitory phosphorylation of
insulin receptor substrate 1 (IRS1) (Griffin et al., 1999; Li et al.,
2004). Phosphorylated IRS1 dissociates from the insulin
receptor, leading to decreased signaling via PI3K/AKT and
reduced glucose uptake (Li et al., 2004; Griffin et al., 1999).
PKC isozymes are divided into three groups: conventional
PKCs (PKCa, PKCbI, PKCbII, and PKCg), novel PKCs (PKCd,
PKCq, PKCε, and PKCh), and atypical PKCs (PKCz and PKCi).
Although PKCa, -d, and -ε are broadly expressed, other
isozymes have a more restricted expression. For example,
PKCq is mainly expressed in T lymphocytes and in some tumors
(Marsland and Kopf, 2008; Griner and Kazanietz, 2007). Because
of the lack of selectivity of available PKC modulators, the role
played by each isozyme in tumorigenesis is not well understood
(Griner and Kazanietz, 2007).erized by enhanced dependence on glucose. Targeting the
al of the scientific community. The natural product EA selec-
olytic tumor cells by promoting insulin resistance and inhib-
shock transcription factor HSF1, thereby enforcing glucose
ue cytotoxic agent.
Table 1. EA Cytotoxicity Correlates with Glucose Sensitivity in a Panel of Cell Lines
Cell line Origin of the tissue EA (IC50) 2-DG (IC50)
786-0 Kidney cancer (VHL/) (Williams et al., 1978) 50 nM 60 mM
786-0/VHL VHL-restored cell line (Tong et al., 2011) >10 mM >1 mM
UOK257 Kidney cancer (FLCN/) (Yang et al., 2008) 65 nM 285 mM
UOK257WT FLCN-restored cell line (Hong et al., 2010) >10 mM 721 mM
UOK262 Kidney cancer metastasis (FH/) (Yang et al., 2010) 35 nM 222 mMa
UOK262WT FH-restored cell line (Tong et al., 2011) >10 mM >1 mMa
HK2 Normal kidney (proximal tubule) (Ryan et al., 1994) >10 mM >1 mM
HEK293 Embryonic epithelial kidney cell (Pear et al., 1993) >10 mM >1 mM
PC3 Prostate cancer (Kaighn et al., 1979) 5 mM 300 mM
SKBr3 Breast cancer (Fogh and Trempe, 1975) 3 mM n/a
Cells (70%confluence) were treatedwith a range of EA concentrations (1 nM–10 mM) in serum-freemedia. After 48 hr, viability wasmeasured byMTT or
manual cell counting. For UOK262 and UOK262WT, viability was only assessed by manual cell counting. Molecularly restored kidney cancer cell lines
and normal kidney cell lines did not show significant sensitivity toward EA. Glucose dependence of the cells was similarly assessed by determining
sensitivity to 2-deoxyglucose (2-DG, 10 nM100 mM). Cells were cultured in DMEM containing 1g/l glucose and were treated with 2-DG for 72 hr
(786-0, 786-0/VHL, UOK257, UOK257WT, HK2, HEK293, PC3, and SKBr3), aexcept for UOK262 and UOK262WT, which were treated for 24 hr.
Viability was assessed by MTT and/or manual cell counting as above. EA sensitivity displays a highly significant positive correlation with glucose
dependence, as assessed by determining R2 and the Pearson Correlation Coefficient (R2 = 0.9126; Pearson Correlation Coefficient = 0.962; p =
0.000003). UOK262 data were not included when determining R2 and the Pearson Correlation Coefficient because they were exposed to 2-DG for
24 hr and not 72 hr like the other cell lines.
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PKCq Mediates Cytotoxic Activity of Englerin AThe epoxyguaiane englerin A (EA) is a natural product that
displays selective in vitro cytotoxicity toward kidney cancer
cell lines in the NCI-60 cell line panel (Ratnayake et al., 2009).
Because EA’s cytotoxicity profile suggests a unique mecha-
nism of action, we sought to identify EA’s molecular target(s)
in order to provide potentially novel therapeutic anticancer
strategies.
RESULTS
EA Is Selectively Cytotoxic for a Panel of Genetically
Defined Kidney Cancer Cell Lines
Using cell lines derived from three genetically defined kidney
cancers (Clear Cell Renal Cell Cancer, 786-0; Hereditary Leio-
myomatosis Renal Cell Cancer, UOK262; Birt-Hogg-Dube´
Syndrome, UOK257) and their molecularly restored (e.g., stable
re-expression of VHL, FH, or Folliculin, respectively; see refer-
ences in Table 1) nontumorigenic isogenic counterparts, we
assessed EA cytotoxicity by MTT assay and/or manual cell
counting (Table 1). Whereas the three genetically defined kidney
cancer cell lines displayed an IC50 for EA of 35–50 nM, in each
case the molecularly restored isogenic counterpart was mark-
edly less sensitive to EA (IC50 > 10 mM). Two nontumorigenic
kidney-derived cell lines, HK2 and HEK293, were similarly insen-
sitive to EA (IC50 > 10 mM). In contrast, the prostate cancer cell
line PC3 and the breast cell line SKBr3 displayed intermediate
sensitivity to EA (IC50 = 3–5 mM). Sensitivity to EA correlated
significantly with sensitivity to 2-deoxyglucose (2-DG), an
indicator of glucose dependence (Table 1).
EA Selectively Activates PKCq
Because nothing is known about EA’s mechanism of action, we
predicted potential target(s) by structure activity relationship
analysis (see the Experimental Procedures). Fifteen potential
molecular targets were identified, half of which were isoformsCof protein kinase C (PKC) (Table S1 available online). Therefore,
we investigated further the potential effect of EA on PKCs, first
using a pan-PKC kinase assay. We found that treatment of
whole-cell extracts with EA increased pan-PKC activity in
a dose-dependent manner (Figure 1A; Figure S1). To identify
which PKC isoforms were responsive to EA, we individually
silenced expression of PKC-a, -d, -q, -h, or -ε in 786-0 cells
and examined the impact on EA cytotoxicity. Only PKCq knock-
down abrogated EA cytotoxicity (Figure 1B), suggesting that
PKCq may be a target of EA. We confirmed this hypothesis by
evaluating the effect of EA on the enzymatic activity of purified
PKCq in vitro. We found that PKCq-mediated phosphorylation
of its substrate IRS1 was dose-dependently enhanced by EA
(Figures 1C and 1D).
Because PKCq is structurally very similar to PKCd, we asked
whether EA’s effect on PKC activity is due solely to PKCq activa-
tion. Phorbol esters, including the fluorescent analog sapintoxin
D (SAPD), bind to the same pocket in PKCs as does diacylgy-
cerol (DAG) and are well-known PKC activators. Unlike PKCq
and PKCd, conventional PKCs, including PKCa, require priming
with Ca2+ in order to bind either DAG or phorbol esters (Luo and
Weinstein, 1993; Griner and Kazanietz, 2007). In vitro kinase
assay (in the absence of Ca2+) using either PKCa, -d, or -q
proteins confirmed that EA selectively activates PKCq. In
contrast, SAPD activated both PKCd and PKCq under the
same assay conditions (Figure 1E).
Finally, we took advantage of the fluorescent properties of
SAPD to confirm the binding of EA to PKCq (Figure 1F). Purified
PKCq was incubated for 20 min with EA (1 mM) or DMSO prior
to the addition of SAPD (2 mM). We found that premixing
PKCq with EA significantly reduced SAPD binding, supporting
the hypothesis that EA interacts with a motif in PKCq, either
contiguous with or close to the SAPD/DAG binding domain.
Premixing EA with PKCd had no effect on SAPD binding
(data not shown).ancer Cell 23, 228–237, February 11, 2013 ª2013 Elsevier Inc. 229
Figure 1. EA Is a Selective PKCq Activator
(A) Pan-PKC kinase activity was assessed in 786-0
cells following EA treatment. Whole-cell lysates
were incubated for 1 hr at 30C with EA or DMSO
in the presence of ATP (10 mM). PKC kinase
activity was quantified by spectrophotometry (see
the Experimental Procedures).
(B) Viability (determined by MTT assay) after 24 hr
EA treatment (100 nM) of 786-0 cells silenced for
different PKC isoforms by RNA interference.
(C) Effect of 30 min EA (100 nM) treatment on
PKCq-mediated phosphorylation of IRS1. A
radioactive kinase activity assay was performed
in the presence of 6 mCi (0.2 mM) of [32P]-ATP and
10 mM nonradioactive ATP using purified PKCq
(50 ng) and its substrate IRS1 (50 ng).
(D) Nonradioactive dose-dependent effects of
EA on PKCq-mediated phosphorylation of IRS1-
S1101 using purified proteins were assessed by
immunoblotting (1 hr treatment; 10 ng PKCq, 20 ng
IRS1). The last lane omits IRS1 and is a negative
control.
(E) Purified PKCa, PKCd, or PKCq (5 ng) were
incubated for 1 hr with DMSO, SAPD (2 mM), or EA
(1 mM) in presence of ATP (10 mM). PKC kinase
activity was quantified by spectrophotometry.
(F) EA competes with the fluorescent phorbol
ester SAPD for binding to PKCq. EA (1 mM)
was preincubated for 20 min with 5 ng purified
PKC protein prior to addition of SAPD (2 mM).
SAPD fluorescence shifts from 455 nm to 420 nm
when it is bound to PKC. Thus, fluorescence
emission was measured at 420 nm (excita-
tion at 355 nm) to assess SAPD binding in pres-
ence or absence of EA (*p < 0.05). Data are
displayed as the mean ± SD (see also Figure S1
and Table S1).
Cancer Cell
PKCq Mediates Cytotoxic Activity of Englerin APKCq Activation Induces an Insulin-Resistant
Phenotype in Tumor Cells
Because we demonstrated that EA enhanced PKCq-mediated
inhibitory phosphorylation of IRS1 (on S1101) in vitro, we hypoth-
esized that EA might induce an insulin-resistant phenotype. EA
enhanced the inhibitory phosphorylation of IRS1 in 786-0 cells
and led to reduced activating phosphorylations of AKT (T308
and S473) and reduced AKT-mediated phosphorylation of
GSK3b (S9). These effects are PKCq-dependent because they
were ameliorated upon siRNA-mediated silencing of PKCq
(Figure 2A). EA also reduced glucose uptake in 786-0 cells, to
a similar degree as the Glut1 inhibitor fasentin (Figure 2B), and
decreased cellular ATP content as well (Figure 2C). However,
at the concentration used, fasentin only slightly affected 786-0
cell viability (Figure S2A), whereas addition of cell permeable
pyruvate (methylpyruvate) abrogates EA cytotoxicity (Fig-
ure S2B). These data suggest that glucose uptake inhibition
contributes to but does not solely account for EA cytotoxicity.
Next, we assessed the role played by insulin pathway inhibi-
tion in EA-mediated inhibition of AKT. We confirmed that the
inhibitory effect of EA on AKT activity was IRS1-dependent
because EA-mediated AKT inhibition was overcome by the230 Cancer Cell 23, 228–237, February 11, 2013 ª2013 Elsevier Inc.inclusion of EGF in the culture media (Figure S2C). To confirm
the importance of IRS1-dependent AKT inhibition for EA cyto-
toxicity, we infected 786-0 cells with several AKT viral
constructs. As shown in Figure 2D (upper panel), expression of
dominant negative AKT (AktDN) enhanced EA cytotoxicity,
whereas expression of constitutively active AKT (AktCA)
protected cells from EA. These impacts on EA cytotoxicity
were consistent with AKT activity status (Figure 2D, lower panel;
Figure S2D), and the data clearly implicate IRS1-dependent
inhibition of AKT as a necessary component of the cytotoxic
response to EA.
To determine whether the in vitro cytotoxicity of EA was
obtainable in vivo, we treated athymic mice bearing 786-0 tumor
xenografts with EA (5 mg/kg intraperitoneally, daily except
Sunday). EA markedly inhibited tumor growth during the
2-week treatment period (Figure 2E). In agreement with our
in vitro data, inhibitory phosphorylation of IRS1 was increased,
and activity of the PI3K/AKT pathway was decreased in 786-
0 tumors excised from mice treated with EA, when compared
to tumors from vehicle-treated mice (Figure 2F). Importantly, in
a second tumor xenograft model, EA inhibited human prostate
tumor growth by up to 60% (Figure S2E), consistent with its
Figure 2. EA Induces Insulin Resistance In Vitro and In Vivo
(A) EA-mediated phosphorylation of IRS1 (S1101), AKT (pT308 and pS473), and GSK3b (pS9) in 786-0 cells requires PKCq expression. EA treatment (10 mM) was
for 6 hr.
(B) EA inhibits glucose uptake in 786-0 cells as shown by using the nondegradable fluorescent glucose analog 2-NBDG. The Glut1 inhibitor fasentin (50 mM) is
shown as a positive control. EA and fasentin treatments were for 3 hr.
(C) Effect of EA treatment (6 hr, 1 mM) on ATP levels in 786-0 cells was measured using ATPlite assay.
(D) Effect of AKT activation on EA cytotoxicity. 786-0 cells were infected 24 hr prior to EA treatment with AKT lentiviral constructs: wild-type AKT (AktWT),
dominant negative AKT (AktDN), or constitutively active AKT (AktCA). After treatment with 1 mM EA for an additional 24 hr, cell viability was assessed by manual
cell counting with trypan blue exclusion (upper panel). Impact of lentiviral infections on AKT activity is shown in the lower panel and in Figure S2D. EA inhibits the
activity of wild-type but not of constitutively active AKT.
(E) Effect of EA treatment (5 mg/kg, daily except Sunday) on xenograft growth of 786-0 cells in athymic mice (vehicle: PBS/DMSO, 1/1). The left panel displays the
growth curve of one of two animal experiments, each with eight animals per group. The right panel represents the averagedmean end point tumor volumes of the
two experiments (32 animals in total).
(F) EA treatment in vivo stimulates inhibitory phosphorylation of IRS1 (pS1101) and reduced phosphorylation of the AKT substrate GSK3b (pS9) in tumor
xenografts of treated mice. *p < 0.05. Data are displayed as the mean ± SD (see also Figure S2).
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PKCq Mediates Cytotoxic Activity of Englerin Aability to stimulate PKCq in these cells and with its in vitro toxicity
profile (Figure S1; Table 1).
PKCq Induces Heat-Shock-Independent Activation
of HSF1
Because the in vivo data support further evaluation of EA as an
anticancer agent, we asked whether treated animals might
develop hyperglycemia because of induction of systemic insulin
resistance. We measured blood glucose level in mice harboringCeither 786-0 or PC3 xenografts before and following a single
treatment with either EA or vehicle (PBS/DMSO, 1:1). Surpris-
ingly, mice treated with EA displayed significantly lower blood
glucose compared to vehicle-treated mice (Figure 3A).
Chemically induced reduction in blood glucose has been re-
ported previously and is thought to be due to increased
HSP70, resulting in sensitization of cells to insulin (Chung
et al., 2008; Kavanagh et al., 2011). We observed that in mice
treated with EA both plasma and tumor HSP70 were elevatedancer Cell 23, 228–237, February 11, 2013 ª2013 Elsevier Inc. 231
Figure 3. EA Activates HSF1
(A) Effect of EA on blood glucose level in tumor-
bearing mice prior to (‘‘basal level’’) or 5 min after
treatment with EA (EA, 5 mg/kg; vehicle: PBS/
DMSO, 1/1).
(B) Quantification of plasma HSP70 level in tumor-
bearing mice 4 hr following EA treatment (EA:
5 mg/kg; vehicle: PBS/DMSO, 1/1).
(C) HSP70 protein expression following EA treat-
ment of 786-0 cells in vitro (EA, 1 mM for 8 hr) and
in vivo (786-0 xenografts; prior to and 8 hr after EA,
5 mg/kg) was assessed by immunoblotting.
(D) EA stimulation of HSF1 transcriptional activity
requires PKCq expression. HSF1 activity was
measured in cells transiently transfected with
a HSP70 HSE-promoter GFP-tagged reporter
plasmid 6 hr after EA treatment.
(E) EA cytotoxicity is affected by HSF1 activation
and extracellular glucose concentration. BGP-15
prolongs the HSF1 transcriptional response. High
glucose medium contains 4.5 g/l glucose; low
glucose medium contains 1 g/l glucose. BGP-15
was used at 50 mM (Chung et al., 2008) and EAwas
used at 1 mM. Incubation was for 24 hr. Viability
was assessed by MTT assay and confirmed by
manual cell counting of trypan blue-excluding
cells using a hemacytometer. *p < 0.05; **p <
0.001. Data are displayed as the mean ± SD (see
also Figure S3).
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PKCq Mediates Cytotoxic Activity of Englerin Acompared to vehicle-treated mice (Figures 3B and 3C). HSP70 is
a marker of cell stress and is a transcriptional target of HSF1
(Trepel et al., 2010). Consistent with these data, we observed
that EA induced HSF1 nuclear translocation and upregulated
its transcriptional activity in a PKCq-dependent manner (Figures
3D and S3).
Because HSF1 has recently been identified as a contributing
factor for tumorigenesis and likely represents a nononcogene
addiction of most tumor cells (Whitesell and Lindquist, 2009;
Santagata et al., 2011; Dai et al., 2007; Mendillo et al., 2012;
Min et al., 2007), we investigated whether HSF1 activation might
compromise EA cytotoxicity, much as it is thought to compro-
mise the cytotoxicity of HSP90 inhibitors (which also induce
HSF1 [Zou et al., 1998]). We examined the impact of the HSF1
chemical enhancer BGP-15, currently under clinical evaluation
for treating insulin-resistance disorders (Chung et al., 2008;
Litera´ti-Nagy et al., 2009; Hargitai et al., 2003), on EA-induced
cytotoxicity. To our surprise, addition of BGP-15 significantly
increased EA cytotoxicity (Figure 3E, left panel). We have shown232 Cancer Cell 23, 228–237, February 11, 2013 ª2013 Elsevier Inc.that PKCq induced insulin resistance in
tumor cells, and Dai et al. (2007) demon-
strated that HSF1 enforces glucose
dependence in tumor cells. Thus, we
hypothesized that the increased cytotox-
icity obtained in vitro upon combination
of BGP-15 and EA might result from the
simultaneous occurrence of these two
metabolic events. If this were the case,
the cytotoxicity of an EA/ BGP-15 drug
combination should be augmented in
cells exposed to low glucose. Indeed,as shown in Figure 3E (right panel), BGP-15 and EA, either
administered as individual agents or in combination, displayed
greater cytotoxicity when tumor cells were cultured in low
glucose media.
EA Cytotoxicity Requires Expression of Both PKCq
and HSF1
Next, we asked whether HSF1 expression is necessary for EA-
induced cytotoxicity. Using shRNA to knock down HSF1 (Fig-
ure S4A), we found that HSF1 expression, like PKCq, is essential
for cell sensitivity to EA (Figure 4A). Importantly, the synergistic
effect obtained by combining BGP-15 and EA (see Figure 3E)
also depended on HSF1 expression. To provide further support
for our hypothesis that both PKCq and HSF1 are necessary for
EA cytotoxicity, we made use of the fact that HEK293 cells are
insensitive to EA (see Table 1), express undetectable levels of
endogenous PKCq, and do not overexpress HSF1 (data not
shown). We were able to induce EA sensitivity in HEK293 cells
after transfection with both PKCq and HSF1 but not after
Figure 4. PKCq and HSF1 Are Both Neces-
sary for EA Cytotoxicity in Tumor Cells
(A) EA sensitivity of 786-0 cells to EA and EA/BGP-
15 requires HSF1 expression. EA was used
at 1 mM and BGP-15 at 50 mM (24 hr). HSF1
expression was decreased by transfection of
HSF1-specific shRNA 24 hr prior to treatment. *p <
0.05 (compared to control); #, p < 0.05 (compared
to EA-treated).
(B) HEK293 cells are not sensitive to EA. HSF1 and
PKCq overexpression confers EA sensitivity on
HEK293 cells (EA treatment was for 24 hr at 1 mM,
commencing 24 hr after transfection). *p < 0.05
(compared to cotransfected control).
(C) Interaction of endogenous HSF1 and PKCq in
786-0 cells was visualized by immunoprecipitation
of endogenous PKCq and blotting for associated
HSF1. 786-0 cells grown in 6-well plates were
lysed in TNESV buffer. The lysates were treated for
1 hr with EA (100 nM) or DMSO at 30C before
immunoprecipitation. HSP90 interaction with the
PKCq/HSF1 immunocomplex was reduced by EA
treatment (left panel). The inputs for this experi-
ment can be found in Figure S4C.
(D) EA stimulates PKCq-mediated phosphoryla-
tion of purified HSF1 in vitro (50 ng of purified
proteins; treatment for 30 min at 30C).
(E) Identification of a putative PKCq phosphoryla-
tion site on HSF1. HEK293 cells were transfected
with PKCq and either wild-type or point mutated
HSF1 plasmids (see Figures S4E and S4F) and
sensitivity to EA was assessed (treatment for 24 hr
with 1 mM EA).
(F) Effect of HSF1 S333 mutants on EA sensitivity
of HEK293 cells overexpressing PKCq. The
phosphomimetic mutant HSF1-S333E supports
EA cytotoxicity, whereas the nonphosphorylatable
mutant HSF1-S333A does not (treatment for 24 hr
with 1 mM EA).
(G) Association of HSF1-S333A, HSF1-S333E,
and wild-type HSF1 with HSP90. HEK293 cells
were transiently transfected with Flag-tagged
HSF1 plasmids as indicated. After 24 hr, Flag
immunoprecipitates were subjected to SDS-
PAGE, transferred to PVDF membrane, and im-
munoblotted for associated endogenous HSP90.
Anti-HSF1 antibody was also blotted to monitor the uniformity of HSF1 expression and efficiency of immunoprecipitation. The phosphomimetic mutant HSF1-
S333E associates with endogenous HSP90 to a markedly lesser degree than does nonphosphorylatable HSF1-S333A; HSP90 association with wild-type HSF1
is shown for comparison. Band optical densities from two separate experiments were obtained by image analysis software and the HSP90 band density in
each case was normalized to the respective HSF1 band density (graphical insert). The inputs for this experiment can be found in Figure S4H. Data are displayed
as the mean ± SD (see also Figure S4).
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PKCq Mediates Cytotoxic Activity of Englerin Atransfection with either construct alone (Figure 4B; see Fig-
ure S4B for inputs).
Extending our observation that PKCq is necessary for HSF1
activation by EA (Figure 3D), we were able to detect the interac-
tion of endogenous PKCq and HSF1 in 786-0 cells (Figure 4C;
see Figure S4C for inputs). In addition, we found that PKCq
phosphorylated HSF1 in vitro in the presence of EA (Figure 4D),
and EA-induced serine phosphorylation of endogenous HSF1
in 786-0 cells was PKCq-dependent (Figure S4D). Further, we
observed that HSP90 was also a component of the HSF1/PKCq
complex but was dissociated after treatment with EA (Figure 4C).
Because dissociation from HSP90 is a prerequisite for HSF1
activation (Anckar and Sistonen, 2011; Zou et al., 1998), theseCdata suggest that PKCq phosphorylation of HSF1 may promote
this process. To identify a putative PKCq phosphorylation
site(s) on HSF1, we mutated several predicted PKC consensus
phosphorylation sites (see Figure S4E), and we examined the
ability of these HSF1 mutants to complement exogenous PKCq
in mediating EA cytotoxicity in HEK293 cells (Figure 4E; see
Figure S4F for inputs). EA cytotoxicity was abrogated only
when HSF1 serine 333 was mutated to alanine (S333A),
implicating S333 as a potential PKCq phosphorylation site.
Supporting this possibility, we found that the phosphomimetic
mutant HSF1-S333E, but not the nonphosphorylatable mutant
HSF1-S333A, fully complemented PKCq-dependent EA cyto-
toxicity (Figure 4F; see Figure S4G for inputs).ancer Cell 23, 228–237, February 11, 2013 ª2013 Elsevier Inc. 233
Figure 5. EA Proposed Mechanism of Action: Activation of PKCq
in Cells Expressing HSF1 Leads to Simultaneous Induction of
Insulin Resistance and Glucose Dependence, Resulting inMetabolic
Catastrophe
(A) EA-dependent activation of PKCq stimulates an insulin-resistant phenotype
via inhibitory phosphorylation of IRS1 and inhibition of AKT, limiting access of
tumor cells to glucose.
(B) EA simultaneously stimulates PKCq-mediated phosphorylation and acti-
vation of HSF1, a transcription factor that enforces tumor cell glucose
dependence (Dai et al., 2007).
(C) By simultaneously inducing insulin resistance and glucose dependence,
EA is synthetically lethal to glycolytic tumor cells.
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PKCq Mediates Cytotoxic Activity of Englerin AAlthough the domain of HSF1 that interacts with HSP90 is not
known, S333 is located within the regulatory domain of the tran-
scription factor, a region rich in posttranslational modification
sites and important for the stress inducibility of HSF1 (Anckar
and Sistonen, 2011). Therefore, we examined whether S333
mutation to either alanine or glutamic acid affected HSF1 inter-
action with HSP90. FLAG-tagged HSF1 wild-type, S333A, and
S333E plasmids were transiently transfected into HEK293 cells,
and FLAG immunoprecipitates were probed for associated
endogenous HSP90. Indeed, we found that HSF1-S333A asso-
ciated with endogenous HSP90 to a markedly greater extent
than did HSF1-S333E (Figure 4G; see Figure S4H for inputs).
These data are consistent with the hypothesis that PKCq-
mediated phosphorylation of HSF1 S333 promotes dissociation
from HSP90. Supporting this possibility, we found that HSF1-
S333E was more efficiently activated (>2-fold) by heat shock
when compared to HSF1-S333A (Figure S4I).
DISCUSSION
Survival of tumor cells depends on their ability to adapt to their
environment. Because cellular transformation is associated
with an increased dependence on glucose (Vander Heiden
et al., 2009), tumor cells have reprogrammed their cellular sig-
naling pathways to allow for increased glucose uptake. Indeed,
positron emission tomography with 2-deoxy-2(18F)-fluoro-D-234 Cancer Cell 23, 228–237, February 11, 2013 ª2013 Elsevier Inc.glucose, a nonmetabolizable glucose analog, is frequently
used to distinguish tumors from adjacent normal tissues (Gamb-
hir, 2002), and targeting glucose uptake and/or metabolism
has been explored for its therapeutic potential in treating cancer,
including VHL-deficient kidney cancer (Chan et al., 2011; Hama-
naka and Chandel, 2012). The insulin pathway and the transcrip-
tion factor HSF1 are two examples of evolutionarily conserved
signaling networks that support and foster the glucose depen-
dence of tumor cells (Barbieri et al., 2003; Pirkkala et al., 2001;
Dai et al., 2007).
In this study, we have identified a unique strategy to create
metabolic disaster in glucose-dependent tumor cells by selec-
tively activating PKCq with the natural product EA (schema
illustrated in Figure 5). When examined in a panel of kidney-
cancer-derived cell lines with unique genetic lesions distinct
from VHL deficiency, EA cytotoxicity paralleled sensitivity to
2-deoxy-D-glucose (2-DG), itself an indicator of glucose depen-
dence (see Table 1). In each case, correction of the unique
genetic lesion in isogenic cell lines abrogated both EA sensitivity
and 2-DG cytotoxicity. Nontumorigenic cell lines derived from
normal kidney epithelium were resistant to both EA and 2-DG.
Importantly, however, nontumorigenic HEK293 cells can be
made sensitive to EA by exogenous expression of both PKCq
and HSF1.
Although the crystal structure of EA bound to PKCq will be
necessary to unambiguously identify its binding domain, compe-
tition binding experiments with the fluorescent phorbol ester
SAPD suggest that EA binds within or adjacent to the C1 domain
of PKCq. Because EA is not able to compete with SAPD binding
to PKCd, and because EA is structurally dissimilar from either
phorbol esters or DAG, it is likely that EA has binding require-
ments that are only met in PKCq.
Because of the lack of selectivity of most PKCmodulators, the
unique role of PKCq in cancer biology has remained unclear.
Here, we have identified PKCq as an important pharmacologic
target in glucose-dependent tumor cells. Kim and collaborators
first identified a link between PKCq and insulin resistance when
they demonstrated that PKCq knockout mice were protected
from developing fat-induced insulin resistance (Kim et al.,
2004). We confirmed the association of PKCq with insulin resis-
tance in tumor cells by showing that selective activation of PKCq
disrupts insulin signaling to AKT and induces an insulin-resistant
phenotype reminiscent of that caused in skeletal muscle by
a high fat diet and observed in patients with type 2 diabetes
(Samuel and Shulman, 2012).
We suspect that the lack of hyperglycemia in EA-treated mice
is due to increased HSP70 levels because elevated HSP70 has
been shown to enhance insulin sensitivity (Chung et al., 2008;
Kavanagh et al., 2011). Because EA promoted increased
HSP70 expression in tumor xenografts and in tumor cells
in vitro, we examined the possible impact of EA on HSF1, a
transcriptional regulator ofHSP70 and a protein frequently upre-
gulated in cancer (Whitesell and Lindquist, 2009; Santagata
et al., 2011). As discussed earlier, HSF1 enhances tumor glucose
dependence and the transcription factor, although not trans-
forming on its own, is considered to be a critical contributor to
tumor cell survival (Dai et al., 2007; Solimini et al., 2007).
Recently, HSF1 has been reported to transcriptionally regulate
a number of genes not involved in the heat shock response of
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cells (Mendillo et al., 2012). Thus, inhibition of HSF1 is predicted
to be of therapeutic value in cancer (Whitesell and Lindquist,
2009).
Unexpectedly, although EA stimulates HSF1 transcriptional
activity, we found this to be a prerequisite for EA cytotoxicity.
Thus, we propose that EA is synthetically lethal for tumor cells
that simultaneously express PKCq and are addicted to HSF1.
PKCq activates HSF1 by phosphorylating serine 333 in the stress
responsive regulatory domain. Mutation of this residue to a non-
phosphorylatable (S333A) or phosphomimetic (S333E) amino
acid markedly affects the interaction of HSF1 with HSP90.
Because dissociation of HSF1 from HSP90 is a prerequisite for
HSF1 activation and nuclear translocation (Anckar and Sistonen,
2011), these data provide a mechanistic basis to explain PKCq-
dependent activation of HSF1 by EA. Importantly, EA sensitivity
is strongly correlated with glucose dependence and is most
pronounced when glucose availability is limiting.
In summary, our data show that PKCq-mediated induction of
insulin resistance occurring simultaneously with PKCq-mediated
HSF1 activation is responsible for EA cytotoxicity. PKCq thus
represents a unique molecular target for HSF1-addicted glyco-
lytic tumors, and EA provides a template for designing effective
PKCq-activating drugs.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
The sporadic VHL-deficient kidney tumor cell line 786-0 (Williams et al., 1978),
the prostate cancer cell line PC3 (Kaighn et al., 1979), the breast cancer cell
line SKBr3 (Fogh and Trempe, 1975), the normal kidney cell line HK2 (Ryan
et al., 1994), and HEK293T, an embryonic kidney epithelial cell line (Pear
et al., 1993), were all purchased from ATCC. UOK262, UOK262WT,
UOK257, UOK257-2 (WT), and 786/VHL were established within the Urologic
Oncology Branch. UOK262 is a kidney cancer cell line derived from a metas-
tasis that is deficient in fumarate hydratase (FH) (Yang et al., 2010).
UOK262WT was established by stably transfecting UOK262 with a functional
FH gene (Tong et al., 2011) and is therefore considered to be ‘‘molecularly
restored.’’ UOK257 is a folliculin (FLCN)-deficient kidney tumor cell line derived
from human renal carcinoma of an individual with Birt-Hogg-Dube´ (BHD)
syndrome and its molecularly restored counterpart UOK257-2 (WT) was
established by stably transfecting UOK257 with FLCN (Yang et al., 2008;
Hong et al., 2010). The stably VHL-transfected 786-0 (786/VHL) cell line has
been described previously (Tong et al., 2011). Cells were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) high glucose without sodium pyruvate
(Cellgro, Herndon, VA, USA) or in RPMI-1640 (PC3 only) supplemented with
10% fetal bovine serum (Invitrogen, Grand Island, NY, USA). Viability experi-
ments were performed in serum-free media.
Reagents
EA was generously supplied by R. Akee of the Natural Products Support
Group (Developmental Therapeutics Program, National Cancer Institute,
Frederick National Laboratory, Frederick, MD, USA). Complete mini protease
inhibitor cocktail tablets were purchased from Roche (Indianapolis, IN, USA).
The siRNAs for PKC-a and -z were purchased from OriGene (Rockville, MD,
USA). The siRNAs for PKC-q, -d, and -ε were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Purified HSF1, PKC-q, -a, and -dwere purchased from
EnzoLife Sciences (Farmingdale, NY, USA).
Prediction of EA Targets
Metadrug (Genego, Carlsbad, CA, USA) is a systems pharmacology platform
using QSAR modeling to analyze and compare biological effects of small
molecules. We used it to predict potential targets for EA (see a complete list
of predicted targets in Table S1).CNonradioactive PKC Kinase Assay
PKC kinase activity of cell lysates was measured using the pan-PKC activity
assay from EnzoLife Sciences, following the manufacturer’s recommenda-
tions. Briefly, cells were lysed in TNESV lysis buffer (50 mM Tris, 1% Nonidet
P-40, 2 mM EDTA, 100 mM NaCl, and 2 mM Na3VO4). After 15 min of centri-
fugation (13, 200 rpm, 4C), clarified supernatant was incubated with 10 mM
EA in the kinase buffer provided by the manufacturer (1 hr at 30C with
10 mM ATP). The reaction was stopped by emptying the wells prior to
measuring the phosphorylation of a PKC substrate by spectrophotometry.
PKCa, -d, and -q kinase assays were performed in a similar manner using
5 ng of purified PKC proteins instead of cell lysate (incubation for 1 hr at
30C with 10 mM ATP). Kinase activity was also assessed by incubating
purified PKCq (10 ng) with purified IRS1 (20 ng) in presence of increasing
concentrations of EA (incubation for 1 hr at 30Cwith 10 mMATP). The reaction
was stopped by adding denaturing sample buffer, and phosphorylation of
IRS1 on S1101 was assessed by immunoblot analysis.
Radioactive In Vitro Kinase Assay
Purified IRS1 (50 ng) or HSF1 (50 ng) was incubated with purified PKCq (50 ng)
in presence or absence of EA (100 nM). Reactions were initiated by the
addition of 10 mM nonradioactive ATP and 6 mCi (0.2 mM) of [32P]-ATP and
incubated at 30C for 30 min with periodic mixing. Proteins in the kinase reac-
tions were separated by SDS-PAGE and transferred to PVDF membrane.
Phosphorylation of IRS1 or HSF1 was assessed by radiography of PVDF
membranes. IRS1 or HSF1 were immunoblotted to ensure equal loading.
Phorbol Ester Competition Binding Assay
The fluorescent phorbol ester sapintoxin D (SAPD, 2 mM; Santa Cruz) (Taylor
et al., 1981) was incubated with purified PKC proteins (5 ng) after preincuba-
tion for 20 min with EA (1 mM) or DMSO. Fluorescence of SAPD is shifted
from 455 to 420 nm when it is bound to PKC. Therefore, we monitored fluores-
cence emission at 420 nm to determine SAPD binding to PKC proteins
(Das et al., 2004).
Glucose Uptake Assay
Glucose uptake was measured using a fluorescent nonmetabolizable
D-glucose analog 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-
D-glucose (2-NBDG; Cayman Chemicals, Ann Arbor, MI) as previously
described (O’Neil et al., 2005), with the following modifications. Five thousand
cells were plated in black-well 96-well plates. After treatment as indicated
(3 hr), cells were incubated for 20 min in KREB buffer containing 1g/l glucose
in presence or absence of 20 mM2-NBDG. Cells were then washed three times
for 5 min with PBS to remove all residual extracellular 2-NBDG. The amount of
2-NBDG imported into the cells was measured by assessing fluorescence at
488 nm. The Glut 1 inhibitor fasentin (50 mM; Sigma-Aldrich, St. Louis, MO)
was used as a positive control.
HSP70 Secretion
Plasma HSP70 in tumor-bearing mice was assessed using an ELISA kit
purchased from EnzoLife Sciences and following the manufacturer’s protocol.
Blood was collected 4 hr after EA or vehicle (PBS/DMSO, 1/1) injection.
HSF1 Transcriptional Activity
Cellular HSF1 transcriptional activity was measured using a green fluorescent
protein (GFP)-tag HSE promoter reporter (generously provided by Dr. Luke
Whitesell, Whitehead Institute, Cambridge, MA, USA). Twenty-four hours prior
to analysis, 5,000 786-0 cells were plated in 96-well black-view plates. While
still in suspension, cells were transfected with the reporter plasmid (1 mg
DNA) using lipofectamine LTX (Invitrogen) and following the manufacturer’s
protocol. To avoid potential interference of the phenol red from the media
with the GFP reading, phenol red-free DMEM (high glucose and without
sodium pyruvate) was used instead of regular DMEM. The following day,
786-0 cells were treated as describedwith EA 6 hr prior tomeasure the amount
of GFP produced using a spectrophotometer (488 nm). For HSF1 silencing
experiments, 786-0 cells were transfected with 14 mg of shRNA to HSF1 in
6-well plates using lipofectamine LTX (Invitrogen) 2 days prior to plating into
96-well black-view plates. Nuclear translocation of HSF1 was visualized by
immunofluorescence. Three thousand 786-0 cells were plated in 2-wellancer Cell 23, 228–237, February 11, 2013 ª2013 Elsevier Inc. 235
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PKCq Mediates Cytotoxic Activity of Englerin Achamber-slides (Nunc/Sigma-Aldrich) and treated for 1 hr with EA (1 mM)
before fixation with 4% paraformaldehyde. Cells were blocked 1 hr with BSA
(3%) and permeabilized with Triton (0.5%). HSF1 antibody was incubated
overnight at 4C in a humidified atmosphere. After three washes with TBST
buffer, slides were incubated 1 hr with secondary antibody coupled to
Alexa455, washed, and mounted. DAPI (Cell Signaling Technology, Danvers,
MA, USA) was used to visualize cell nuclei. Pictures were taken with a confocal
microscope (Zeiss NLO510).
Xenograft Tumor Studies
Animal experiments were carried out following the ethical guidelines of the
National Cancer Institute and using an animal protocol approved by the
National Institutes of Health Animal Care Facility. Ten million 786-0 or one
million PC3 cells were implanted subcutaneously on the left flanks of twenty
7-week-old female nude (Nu/Nu) mice (strain code 088; Charles River,
Wilmington, MA, USA). After 1–4 weeks (depending on the cell line), tumors
reached an average volume of 100–150 mm3. Tumor take for both 786-0
and PC3 xenografts was 100%; however, to maintain homogenous group
sizes, only 16 mice out of the 20 were used. Mice were then randomly
separated in two groups of eight mice with comparable tumor volumes and
treated six times a week (daily except Sunday) intraperitoneally with either
EA at 5 mg/kg or vehicle (PBS/DMSO, 1/1). Food and water were available
ad libitum. Tumors were measured throughout the duration of the experiment
using calipers and tumor volumes were estimated using the formula (l3w2)/2.
At the end of the experiment, blood was collected, and tumors were surgically
excised and frozen for further analysis. Animal experiments were performed
twice with eight animals per group each time.
Statistics
Unless specified, all values are expressed as the mean ± standard error.
Values were compared using the Student-Newman-Keul’s test. p < 0.05 was
considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one table, four figures, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
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